Dabrafenib + trametinib (Tafinlar and Mekinist)

Dabrafenib + trametinib at a glance

Dabrafenib and trametinib are two targeted cancer medicines taken together. Dabrafenib is a BRAF inhibitor and trametinib is a MEK inhibitor. Familiar brands are Tafinlar and Mekinist. They are prescribed when a suitable change in the cancer's BRAF gene has been confirmed. This guide is mainly for adults taking dabrafenib capsules and trametinib tablets; children's doses and liquid preparations need their own instructions.

The most useful preparation is a written daily schedule, a thermometer, and the cancer team's day-and-night telephone number. Fever is particularly important with this combination: it may come from the drugs, infection, or another cause, and deserves prompt assessment. A planned treatment break can be part of safe care; it does not automatically mean that treatment has failed.

How dabrafenib + trametinib works

Cancer cells receive signals telling them to grow. In a cancer with a relevant BRAF change, part of this signalling system can remain switched on. Dabrafenib blocks altered BRAF and trametinib blocks MEK, a related step farther along the same pathway. Blocking both steps can control the cancer more effectively than blocking BRAF alone in the settings where this combination has been studied.

Targeted does not mean that only cancer cells are affected. Healthy tissues also use these signals, which helps explain skin, eye and heart problems. The treatment may shrink cancer, keep it stable, or reduce recurrence risk after surgery, depending on why it was prescribed. The likelihood and purpose of benefit should be discussed using your own diagnosis and test results, rather than another person's experience.

How the team decides whether it is suitable

The team checks the actual BRAF report, the cancer type, previous treatment, general health and treatment goal. A suitable BRAF V600 change is required; having cancer in an organ where this treatment is sometimes used is not enough. Melanoma and certain lung cancers are familiar examples. Other specialist uses exist, but suitability cannot be inferred from a gene name alone.

The decision also takes account of heart or eye disease, kidney and liver function, diabetes, bleeding or clotting problems, and whether you can manage the medicines safely at home. Tell the team about previous severe reactions to targeted therapy. International approvals and access differ; this information does not establish Indian approval, funding or availability for a particular use.

Before treatment starts

Bring all prescription medicines, non-prescription products, supplements and traditional remedies to the first medication review, or bring clear photographs of their packaging. Tell the team about past heart failure, abnormal heart rhythm, high blood pressure, blood clots, eye inflammation, retinal disease, lung problems and glucose-6-phosphate dehydrogenase deficiency, often called G6PD deficiency.

Baseline checks commonly include blood counts, liver and kidney tests, blood chemistry, blood pressure, skin assessment and an assessment of heart pumping function, usually an echocardiogram. Diabetes may require additional glucose monitoring. Pregnancy testing is arranged when relevant. Record any pre-existing cough, blurred vision, bowel changes or skin lesions so later changes can be interpreted accurately.

Ask the pharmacist to write down each drug's strength, number of capsules or tablets, times, food interval and missed-dose rule. Ask for a fever plan identifying when to hold both medicines, whom to call and how restart instructions will be provided. Keep the plan accessible to anyone who helps with your medicines.

How to take dabrafenib + trametinib

Daily schedule and food

Dabrafenib is usually taken twice daily, about 12 hours apart. Trametinib is taken once daily, at the same time as one of those doses. Adults commonly receive dabrafenib 150 mg twice daily and trametinib 2 mg daily initially, but your prescribed dose may be different. Dose reductions should come from the cancer team, never from comparing prescriptions with another patient.

For capsules and tablets, take the medicines on an empty stomach: at least one hour before food or at least two hours after food. Swallow them whole with water. A workable schedule might place the first dose before breakfast and the second sufficiently after the evening meal; ask the pharmacist to check the actual times against your routine. Do not open capsules or crush tablets to solve a swallowing difficulty. Suitable alternative formulations may be possible, with different preparation instructions.

Missed doses and vomiting

For dabrafenib, skip a missed dose when the next dose is within six hours. For trametinib, skip it when the next dose is within 12 hours. Otherwise follow the dispensing instructions for taking it when remembered. Never double a dose. If the timing is exactly at a cutoff and your leaflet is unclear, ask the pharmacist rather than guessing. If you vomit after either medicine, do not replace the dose; take the next scheduled dose unless the team advises a treatment hold.

Storage and supply

Keep each medicine in its own original container, away from children, moisture, heat and direct sunlight. Retain the drying agent but never swallow it. Storage instructions vary by formulation and market: current tablet products may be stored at room temperature, while older instructions or other formulations differ. Follow the label on the pack you actually receive, including any after-opening limit. Ask about transport during hot weather or a power cut before a problem occurs.

Monitoring and checking response

Blood tests look for changes that may not yet cause symptoms. Blood pressure, skin and heart function are reassessed; the US labels specify heart imaging after one month and then every two to three months, with extra assessment if symptoms develop. Eye examination is urgent if vision changes. Diabetes can become harder to control, so tell the team about unusual thirst, frequent urination or higher home glucose readings.

Scans and clinical review answer a separate question: whether treatment is achieving its aim. A normal liver test does not prove cancer control, and feeling tired does not prove progression. Keep a brief record of doses, fever, bowel symptoms, appetite and day-to-day function. Bring it to appointments, but contact the team immediately for urgent symptoms instead of waiting to complete a diary.

Common side effects and practical care

Fever, chills and feeling unwell

Fever, shaking chills and flu-like aching are characteristic problems. They can lead to dehydration, low blood pressure and kidney injury. At 38°C or higher, withhold both medicines and contact the cancer team promptly; follow any stricter threshold or earlier hold instruction in your own fever plan. For recurrent fever, the team may instruct you to hold both drugs at the first symptoms, before the temperature reaches 38°C. Infection still needs consideration even when you have had drug-related fever before. Do not restart simply because paracetamol lowers the temperature.

Tiredness, nausea and bowel changes

Tiredness can fluctuate. Choose manageable activity, allow recovery time and report a sudden deterioration. Small meals may be easier when appetite is poor. Use prescribed anti-sickness treatment as directed. For loose stools, record frequency, drink regularly if you are not fluid-restricted, and seek advice early if diarrhoea persists. Inability to drink, reduced urine, dizziness, blood in stools or severe abdominal pain require prompt help.

Skin changes and aches

Rash, dry skin, itching, headaches and joint or muscle discomfort may occur. Use gentle skin products and sun protection, and ask before applying medicated creams. Report a painful rash, blistering or mouth involvement promptly. Show the team any new lump, wart-like growth, changing mole or sore that fails to heal. A skin check remains important even if the cancer being treated is not a skin cancer.

Important side effects to recognise

Heart, lungs and blood clots

Trametinib can reduce heart pumping strength. New breathlessness, swollen ankles, a rapid increase in weight or difficulty breathing when lying down should be reported promptly. New cough or worsening breathlessness may also signal lung inflammation. Sudden chest pain, severe breathlessness, collapse, coughing blood or a painful swollen leg needs urgent assessment for a clot or another serious cause.

Eyes, bleeding and severe abdominal pain

Eye inflammation and retinal problems can threaten sight. Report blurred vision, eye pain, unusual light sensitivity, halos or a new dark area in vision immediately; do not wait for a routine eye appointment. Serious bleeding can occur. Vomiting blood, black tar-like stools, a severe unfamiliar headache, weakness on one side or sudden confusion requires emergency care. Severe persistent abdominal pain may indicate bowel inflammation or perforation.

Liver, kidneys and severe inflammatory reactions

Blood tests monitor liver and kidney effects. Yellow eyes, very dark urine, markedly reduced urine or severe weakness deserve urgent advice. Rare severe skin or inflammatory reactions can involve several organs. One is haemophagocytic lymphohistiocytosis, or HLH, an excessive immune reaction: persistent fever with swollen glands, bruising, rash or marked deterioration needs immediate advice. G6PD deficiency can increase the risk of breakdown of red blood cells; unusual pallor, breathlessness, yellow eyes or dark urine also needs prompt assessment. A spreading blistering rash, skin peeling, sores on the lips or eyes, persistent fever with marked deterioration, or confusion must not be treated as an ordinary rash or routine drug fever.

Other medicines and vaccinations

Dabrafenib can change the levels of other medicines and can itself be affected by medicines that alter liver enzymes. Interactions can involve antibiotics, antifungals, epilepsy medicines, anticoagulants and herbal products. Hormonal contraception can become less reliable. A pharmacist should check the complete list whenever a medicine is started, stopped or changed. Avoid grapefruit and Seville oranges unless the team specifically advises otherwise.

Do not start antibiotics, steroids, herbal fever remedies or extra anti-inflammatory painkillers without checking. A familiar over-the-counter medicine may be unsuitable during dehydration or abnormal kidney tests. Discuss vaccinations with the team: the type of vaccine, current illness and other cancer treatments affect timing. Do not assume all vaccinations are either prohibited or automatically suitable.

Everyday life during treatment

A simple routine reduces avoidable stress. Use alarms or a written checklist without removing tablets from packaging that must protect them from moisture. If someone else helps, agree who records each dose so it is not taken twice. Ask the hospital pharmacy about the next supply well before you run out.

Work, exercise and travel can often be adjusted around treatment, but discuss plans if they take you away from urgent care or monitoring. Do not drive with blurred vision, significant dizziness or poor concentration. Carry medicines in labelled packaging and take the emergency contact details. Explain to family that fever needs a medical call rather than only rest and a fever tablet. It is reasonable to ask for help with shopping, meals or transport on difficult days.

Fertility, pregnancy and breastfeeding

Both medicines can harm a developing baby. Discuss fertility preservation before starting if future parenthood matters to you. Pregnancy prevention remains necessary even if periods stop. Dabrafenib can reduce the effectiveness of hormonal contraception, so obtain a reliable non-hormonal plan.

For this combination, trametinib's longer precaution applies: use effective contraception during treatment and for four months after the last trametinib dose, with the team confirming the end date against both drugs. Men, including those who have had a vasectomy, with a partner who could become pregnant should use condoms during treatment and for four months afterwards under the US combination precautions. Do not breastfeed during treatment or for four months after the last trametinib dose. Contact the team immediately if pregnancy is possible. Local product instructions should be reconciled before treatment starts.

After a pause or the end of treatment

A pause may allow fever, blood tests or another side effect to settle. Ask whether both medicines are held, the earliest review date and who will authorise restarting. Restarting after complicated fever may require a different dose or prevention plan. Never compensate for a break by taking extra tablets. The team may stop one or both permanently after particular serious reactions.

Continue the agreed monitoring and reproductive precautions after treatment ends. Keep reporting persistent or new symptoms; stopping a medicine does not immediately remove all risk. Return unused medicine through the pharmacy's recommended route. If treatment changes, request a new medicine list and ask explicitly which old prescriptions should no longer be taken.

Frequently asked questions